Alnylam repurchases $34.4M of 1.00% convertible notes due 2027 for ~$51.9M

ALNYLAM PHARMACEUTICALS, INC.

Repurchased $34.4M aggregate principal of 1.00% convertible senior notes due 2027 for total cash cost of approximately $51.9M, including accrued interest.
Remaining outstanding principal after repurchases is $362.8M.
Repurchase price is subject to adjustment based on daily VWAP over a measurement period starting December 11, 2025.
Existing capped call transactions entered upon note issuance remain in effect.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.